Nektar Therapeutics buy blaugold
Start price
20.02.22
/
50%
€9.11
Target price
20.02.23
-
Performance (%)
4.74%
End price
05.03.22
€9.54
Summary
This prediction ended on 05.03.22 with a price of €9.54. With a performance of 4.74%, the BUY prediction by blaugold for Nektar Therapeutics closed with a slight gain. blaugold has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Nektar Therapeutics | 1.589% | 1.589% | 102.838% |
iShares Core DAX® | 1.056% | 1.056% | 18.108% |
iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% |
iShares Nikkei 225® | 2.553% | 4.359% | 17.676% |
iShares S&P 500 | -0.434% | 0.224% | 24.986% |
Comments by blaugold for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics
In the thread Trading Nektar Therapeutics
Buy beendet